Maximum expiratory flow rate at 30 percent of vital capacity above residual volume served as an index of airway obstruction in comparing the effects of leukotriene C and histamine administered by aerosol to five normal persons. Leukotriene C was 600 to 9500 times more potent than histamine on a molar basis in producing an equivalent decrement in the residual volume. The leukotriene C response was slow in onset and prolonged, reminiscent of the effects of aerosol allergen challenge in asthmatic allergic subjects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/science.7063880 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of Leaf Extract on Allergic Inflammation in Immune Cell Lines.
Prev Nutr Food Sci
February 2025
School of Regional Innovation and Social Design Engineering, Kitami Institute of Technology, Hokkaido 090-8507, Japan.
is a perennial plant belonging to the Fabaceae family that is widely distributed across northern Asia. roots have been used as a traditional medicinal herb because of their numerous health benefits. However, the physiological properties of leaves remain unknown.
View Article and Find Full Text PDFBackground: Excessive expression of proinflammatory cytokines after rotator cuff (RC) surgery impairs the quality of tendon-bone interface (TBI) healing. There is evidence that the asthma drug montelukast (MS) inhibits the expression of proinflammatory cytokines. This study was conducted to verify the effect of MS administration on TBI healing after RC repair.
View Article and Find Full Text PDFEffect of montelukast on remission maintenance in patients with ulcerative colitis: a Randomized, double-blind controlled clinical trial.
BMC Gastroenterol
March 2025
Liver and Gastrointestinal Diseases Research Center, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
Background: Considering the role of leukotrienes in inflammatory pathways, and owing to the anti-leukotrienes effect of montelukast, in the present clinical trial, we aimed to assess the effect of montelukast on remission maintenance in patients with ulcerative colitis (UC).
Methods: In the present double-blind randomized controlled clinical trial, 222 volunteer UC patients on high-dose corticosteroid and montelukast were recruited. The patients received 10 mg of montelukast (98 patients) or placebo (124 patients) for 22 weeks.
A Brief Report on a Systematic Review of Real-World Effectiveness Studies of ICS/LAMA/LABA for Treatment of Adults with Asthma in the US.
Pulm Ther
March 2025
Global Real-World Evidence & Health Outcomes Research Organization, GSK, Collegeville, PA, US.
Introduction: Long-acting muscarinic antagonist (LAMA) addition to inhaled corticosteroid/long-acting β-agonist (ICS/LABA) dual therapy is recommended for severe asthma, but its real-world effectiveness is not well established.
Methods: A systematic literature review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) to investigate clinical outcomes in US adults with asthma receiving ICS + LABA + LAMA as multiple-/single-inhaler triple therapy (MITT/SITT). Real-world/observational studies published in English in Embase/MEDLINE databases (2014-2024) and conference abstracts presented 2022-2024 were eligible for inclusion.
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].
Zhonghua Jie He He Hu Xi Za Zhi
March 2025
Bronchial asthma (asthma) is a common chronic respiratory disease. Standardized diagnosis, treatment and effective clinical management are critical to improving asthma control, improving patients' quality of life, and reducing the disease burden. Based on the latest evidence-based research from both domestic and international references, the Asthma Group of the Chinese Thoracic Society has revised the " ()".
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!